A number of research firms have changed their ratings and price targets for Verrica Pharmaceuticals (NASDAQ: VRCA):
- 10/21/2024 – Verrica Pharmaceuticals had its price target lowered by analysts at TD Cowen from $15.00 to $10.00. They now have a “buy” rating on the stock.
- 10/4/2024 – Verrica Pharmaceuticals had its price target lowered by analysts at Royal Bank of Canada from $13.00 to $11.00. They now have an “outperform” rating on the stock.
- 10/3/2024 – Verrica Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
- 10/2/2024 – Verrica Pharmaceuticals had its “hold” rating reaffirmed by analysts at Brookline Capital Management.
Verrica Pharmaceuticals Trading Down 1.9 %
Verrica Pharmaceuticals stock traded down $0.03 during midday trading on Monday, reaching $1.57. The stock had a trading volume of 332,698 shares, compared to its average volume of 437,165. The company has a quick ratio of 2.23, a current ratio of 2.36 and a debt-to-equity ratio of 29.58. The firm has a market cap of $66.60 million, a price-to-earnings ratio of -0.90 and a beta of 1.45. Verrica Pharmaceuticals Inc. has a 52-week low of $1.04 and a 52-week high of $11.41. The company has a fifty day moving average of $2.09 and a 200 day moving average of $5.63.
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $4.70 million. On average, analysts anticipate that Verrica Pharmaceuticals Inc. will post -1.58 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
See Also
- Five stocks we like better than Verrica Pharmaceuticals
- Do ETFs Pay Dividends? What You Need to Know
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- The Significance of Brokerage Rankings in Stock Selection
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- 3 Stocks to Consider Buying in October
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Verrica Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.